An open-labeled, randomized, crossover, single-dose study in healthy male Participants to evaluate the pharmacokinetics, safety, and tolerability of stable isotopologs of atazanavir (ATV), administered as single agents or as combinations of two isotopologs, with a pharmacokinetic comparison to Reyataz

Trial Profile

An open-labeled, randomized, crossover, single-dose study in healthy male Participants to evaluate the pharmacokinetics, safety, and tolerability of stable isotopologs of atazanavir (ATV), administered as single agents or as combinations of two isotopologs, with a pharmacokinetic comparison to Reyataz

Recruiting
Phase of Trial: Phase I

Latest Information Update: 08 Jun 2016

At a glance

  • Drugs Atazanavir; C 10276; CTP 518
  • Indications HIV-1 infections
  • Focus Pharmacokinetics
  • Sponsors Concert Pharmaceuticals
  • Most Recent Events

    • 24 Oct 2011 New source identified and integrated (ClinicalTrials.gov: US National Institutes of Health: NCT01458769).
    • 24 Oct 2011 Additional lead trial investigator and actual patient no. added 47 as reported by ClinicalTrials.gov.
    • 24 Oct 2011 Planned End Date added to 1 Apr 2011 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top